MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis

Citations Over TimeTop 10% of 2014 papers

Abstract

Chemoresistance is one of the causes of poor prognosis in pancreatic cancer patients. However, the mechanisms of resistance remain unclear. Here we screened miRNAs associated with drug resistance in pancreatic cancer, and identified a panel of miRNAs dysregulated in gemcitabine-resistance pancreatic cancer cells, including 13 downregulated miRNAs and 20 upregulated miRNAs. Further studies focusing on miR-497 demonstrated that miR-497 suppressed cells proliferation, decreased the percentage of S phase cells, re-sensitized cells to gemcitabine and erlotinib, and attenuated migration and invasion capacities. Furthermore, fibroblast growth factor 2 and fibroblast growth factor receptor 1 were confirmed as miR-497 targets. Overexpression of miR-497 inhibited tumor growth in vivo. Additionally, miR-497 expression was significantly downregulated in pancreatic cancer tissues compared with tumor-adjacent samples (P=0.000). Low expression of miR-497 was an independent adverse prognostic factor of pancreatic cancer (P=0.01, hazard ratio=2.762, 95% confidence interval: 1.159-6.579). Together these results indicate that miR-497 could be a new therapeutic target and prognostic marker of pancreatic cancer.

Related Papers

• → A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance(2017)74 cited
• → Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer(2021)9 cited
• → Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer(2016)11 cited
• → Aberrant expression of circulating microRNAs in pancreatic cancer patients and in patients with gemcitabine resistance(2014)
• → Faculty Opinions recommendation of A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.(2014)